Why Johnson & Johnson Is Outperforming the Dow

J&J has crushed the Dow Jones Industrials so far this year. Can it continue to outperform?

Apr 22, 2014 at 9:30AM

After setting record highs in 2013, the Dow Jones Industrials (DJINDICES:^DJI) has largely traded sideways so far in recent months, down just 0.20% in 2014. Given the general weakness among health care stocks of late, you might suspect that pharma companies have been some of the more problematic components of the Dow. But you'd be wrong. As I discussed recently, Merck (NYSE:MRK) is one of the blue-chip index's hottest companies this year, rising almost 14% and standing only behind Caterpillar as the Dow's best-performing stock of 2014. Another health care stock, Johnson & Johnson (NYSE:JNJ), has gained nearly 9% to become the Dow's third best-performing stock this year. Let's look at why J&J stock has been crushing most of its Dow peers and fellow health-care companies of late.

Drug sales power consensus-beating 1Q earnings
J&J last Tuesday posted first-quarter earnings per share of $1.54, which was $0.06 higher than the Wall Street consensus. Revenue also came in over $110 million higher than consensus at $18.1 billion for the quarter. The majority of the year-over-year growth came from the company's pharmaceutical segment: Drug sales increased 10.8% year over year, even though J&J lost exclusivity for its proton pump inhibitor Aciphex.  

Management attributed strong sales in pharmaceuticals to the launch of new products and growth in emerging markets. Stelara, an anti-inflammatory drug used to treat plaque psoriasis, saw global sales increase by 31.8% for the full year. J&J's schizophrenia drug Invega also saw global sales increase by 31.3%, driven primarily by growth in foreign markets. And the company's HIV drug Prezista saw sales climb by 21.3% for the year.

For newly launched products, J&J reported that its hepatitis C combo therapy Olysio is off to a strong start, generating $354 million in global sales in its first quarter on the market. The fact that Olysio is on track to become a blockbuster in its first year on the market is particularly noteworthy in light of the simultaneous launch of Gilead Sciences(NASDAQ:GILD) competing therapy Sovaldi. It appears that some doctors are probably prescribing the two drugs together. J&J's relatively new prostate cancer drug Zytiga also continued to impress, growing global sales by 48.8%  despite facing increased competition from Medivation's Xtandi. 

Can J&J continue to outperform?
Following its earnings beat, J&J promptly raised its full-year guidance for 2014 to $5.80 to $5.90 per share. And there is a chance that the company will even beat this increased guidance. Putting aside more growth from key products such as Zytiga, there is J&J's new leukemia drug Imbruvica, co-developed with Pharmacyclics (NASDAQ:PCYC). J&J and Pharmacyclics split Imbruvica's sales 50/50. Some experts believe the(NASDAQ:PCYC)drug could reach blockbuster status in short order, so J&J could be looking at roughly $500 million in potential sales from this single drug going forward. In sum, sales of new drugs and increasing sales in emerging markets are helping to lift J&J shares higher.  

Foolish wrap-up
J&J may sound like a boring name to have in your portfolio, but this stock is battle-tested. The company has been around for nearly 130 years and has outperformed many of the major indices for close to a decade -- despite losing income from top-selling drugs due to the patent cliff. I am particularly impressed with J&J's cadre of new drugs, and their performance last quarter certainly speaks for itself.

Even so, the wolves could be closing in on J&J's growth in the pharmaceutical market. Specifically, keep a close eye on how Gilead's Sovaldi impacts sales of Olysio, as well as threats from hepatitis C drugs from AbbVie and Enanta Pharmaceuticals that are expected to be approved soon. Merck also has an intriguing hepatitis C therapy that looks clinically superior to Olysio, although it is a few years away from a regulatory review. Imbruvica may face competition from Gilead's experimental drug idelalisib before year's end as well. Idelalisib could be approved later this year, where it will directly compete with Imbruvica as a treatment for chronic lymphocytic leukemia.

J&J's Zytiga has faced fierce competition from a handful of other prostate cancer drugs and it has still posted tremendous growth. I believe this is a testament to J&J's ability to market drugs even in highly competitive markets. You should definitely keep tabs on this top-performing Dow stocking.  

3 stocks to own for the rest of your life
As every savvy investor knows, Warren Buffett didn't make billions by betting on half-baked stocks. He isolated his best few ideas, bet big, and rode them to riches, hardly ever selling. You deserve the same. That's why our CEO, legendary investor Tom Gardner, has permitted us to reveal The Motley Fool's 3 Stocks to Own Forever. These picks are free today! Just click here now to uncover the three companies we love. 

George Budwell owns shares of Gilead Sciences. The Motley Fool recommends Gilead Sciences and Johnson & Johnson. The Motley Fool owns shares of Johnson & Johnson. Try any of our Foolish newsletter services free for 30 days. We Fools may not all hold the same opinions, but we all believe that considering a diverse range of insights makes us better investors. The Motley Fool has a disclosure policy.

Money to your ears - A great FREE investing resource for you

The best way to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as “binge-worthy finance.”

Feb 1, 2016 at 5:03PM

Whether we're in the midst of earnings season or riding out the market's lulls, you want to know the best strategies for your money.

And you'll want to go beyond the hype of screaming TV personalities, fear-mongering ads, and "analysis" from people who might have your email address ... but no track record of success.

In short, you want a voice of reason you can count on.

A 2015 Business Insider article titled, "11 websites to bookmark if you want to get rich," rated The Motley Fool as the #1 place online to get smarter about investing.

And one of the easiest, most enjoyable, most valuable ways to get your regular dose of market and money insights is our suite of free podcasts ... what we like to think of as "binge-worthy finance."

Whether you make it part of your daily commute or you save up and listen to a handful of episodes for your 50-mile bike rides or long soaks in a bubble bath (or both!), the podcasts make sense of your money.

And unlike so many who want to make the subjects of personal finance and investing complicated and scary, our podcasts are clear, insightful, and (yes, it's true) fun.

Our free suite of podcasts

Motley Fool Money features a team of our analysts discussing the week's top business and investing stories, interviews, and an inside look at the stocks on our radar. The show is also heard weekly on dozens of radio stations across the country.

The hosts of Motley Fool Answers challenge the conventional wisdom on life's biggest financial issues to reveal what you really need to know to make smart money moves.

David Gardner, co-founder of The Motley Fool, is among the most respected and trusted sources on investing. And he's the host of Rule Breaker Investing, in which he shares his insights into today's most innovative and disruptive companies ... and how to profit from them.

Market Foolery is our daily look at stocks in the news, as well as the top business and investing stories.

And Industry Focus offers a deeper dive into a specific industry and the stories making headlines. Healthcare, technology, energy, consumer goods, and other industries take turns in the spotlight.

They're all informative, entertaining, and eminently listenable. Rule Breaker Investing and Answers are timeless, so it's worth going back to and listening from the very start; the other three are focused more on today's events, so listen to the most recent first.

All are available for free at www.fool.com/podcasts.

If you're looking for a friendly voice ... with great advice on how to make the most of your money ... from a business with a lengthy track record of success ... in clear, compelling language ... I encourage you to give a listen to our free podcasts.

Head to www.fool.com/podcasts, give them a spin, and you can subscribe there (at iTunes, Stitcher, or our other partners) if you want to receive them regularly.

It's money to your ears.


Compare Brokers